Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
25 and 50 mg diclofenac K film coated immediate release tablets More
Apitoxin is a new biological drug for pain & inflammation and arthritis, approved by the Korean FDA on May 3, 2003 after 14 years of preclinical, animal, and phase I, II & III clinical studies More
The First Line of Therapy in Severe Migraine Attacks More
The omega-3 fatty acids are extracted from New Zealand green lipped mussels and developed into oils for use in anti-inflammatory compounds by our UK based clients. More
Proprietary supercritical fluid (SCF) technology to improve bioavailability, enhance stability and optimise drug delivery for small and large molecules in a range of dosage forms. More
Our clients are sourcing and developing unique omega-3 fatty acids from green lipped mussels for the treatment of joints, asthma and dermatitis in animals. More
Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
Enhancing the dissolution performance of small and large molecules in a range of dosage forms More
Improving the reconstitution and increasing the stability of biomolecules using supercritical fluid (SCF) processing More
Using a unique resin-based topical delivery system, this product provides more effective local pain relief and longer periods of sustained relief compared to existing products. More
Related Reports
Market Research Reports provided by reports.iptechex.com
Oct 2010 - 169 pages - $3,500
Dec 2010 - 31 pages - $500
Nov 2010 - 40 pages - $500
Nov 2010 - 41 pages - $2,000
Apr 2011 - 50 pages - $500
Aug 2011 - 53 pages - $500
Sep 2011 - 74 pages - $500
Feb 2011 - 57 pages - $500
Nov 2010 - 1336 pages - $1,495
Nov 2010 - 50 pages - $500
Your selection
Browse By
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us